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Abstract
Background: Even today, treatment of Stage III NSCLC still poses a serious challenge. So far,
surgical resection is the treatment of choice. Patients whose tumour is not resectable or who are
unfit to undergo surgery are usually referred to a combined radio-chemotherapy. However,
combined radio-chemotherapeutic treatment is also associated with sometimes marked side
effects but has been shown to be more efficient than radiation therapy alone.
Nevertheless, there is a significant subset of patients whose overall condition does not permit
administration of chemotherapy in a combined-modality treatment.
It could be demonstrated though, that NSCLCs often exhibit over-expression of EGF-receptors
hence providing an excellent target for the monoclonal EGFR-antagonist cetuximab (Erbitux®)
which has already been shown to be effective in colorectal as well as head-and-neck tumours with
comparatively mild side-effects.
Methods/design:  The NEAR trial is a prospective phase II feasibility study combining a
monoclonal EGF-receptor antibody with loco-regional irradiation in patients with stage III NSCLC.
This trial aims at testing the combination's efficacy and rate of development of distant metastases
with an accrual of 30 patients.
Patients receive weekly infusions of cetuximab (Erbitux®) plus loco-regional radiation therapy as
intensity-modulated radiation therapy. After conclusion of radiation treatment patients continue to
receive weekly cetuximab for 13 more cycles.
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Discussion: The primary objective of the NEAR trial is to evaluate toxicities and feasibility of the
combined treatment with cetuximab (Erbitux®) and IMRT loco-regional irradiation.
Secondary objectives are remission rates, 3-year-survival and local/systemic progression-free 
survival.
Background
80% of all lung cancers are non small cell carcinomas. For
these tumours, complete surgical resection still yields the
best treatment results so far. However, only 25% of all
patients have the option of surgical treatment.
In the event of the tumour being surgically not resectable
or the patient functionally inoperable, radiation therapy/
combined radio-chemotherapy are the only curative treat-
ment options for lung cancer in a localised stage. In this
case, a dose of 60–66 Gy is usually applied to the tumour
by external beam radiotherapy (EBRT) resulting in a mean
local tumour control of about 12 months [1]. Further-
more, a recent meta-analysis was able to demonstrate
improved results in combined radio-chemotherapy on
platinum-based regimen with a significantly higher 2-
year-survival compared to local irradiation alone [2]. It
could also be shown in various randomised trials that
simultaneous platinum-based radio-chemotherapy is sig-
nificantly superior to sequential regimen [3-5]. Accompa-
nying toxicities are, however, not negligible, especially
considering the simultaneous radio-chemotherapy [3]
which is the reason for many patients proving ineligible
for a combined treatment.
Other potential partners for combined treatment are
monoclonal antibodies. NSCLCs often show an over-
expression of epidermal growth factor receptors (EGFR)
[6,7] also associated with a less favourable prognosis. In
pre-clinical experiments EGFR inhibition was able to
show a reduction of cell proliferation, an increase of apop-
tosis, and a reduction of angiogenesis [8,9].
Cetuximab is a monoclonal antibody which binds to the
extracellular EGF-receptor domain hence inhibiting intra-
cellular phosphorylation of EGFR and consecutive down
stream signalling. This in turn causes cell cycle arrest and
increased expression of pro-apoptotic enzymes.
Combining irradiation and cetuximab exposure, a syner-
gistic and/or additive effect could be demonstrated in
NSCLC cell lines in vitro [10].
In the case of squamous cell carcinoma of the head and
neck, a G0/G1-cell cycle arrest could be observed with the
radiation-induced damage exhibiting a reduction of repair
and an increase in apoptosis compared to irradiation
alone [9-11].
There are various phase I-III trials which were able to dem-
onstrate that cetuximab can be safely administered as a
single drug and also in combination with irradiation [14-
19].
In a large phase III trial, patients with head and neck
tumours were randomized either to irradiation alone or in
combination with cetuximab. 424 patients were enrolled
in this trial showing a significantly higher 3-year survival
of 55% in the combined treatment vs. 45 % for irradiation
alone [18]. These encouraging results show a good corre-
lation to results obtained in combined radio-chemother-
apy vs. irradiation alone in locally advanced head and
neck cancer [20]. However, combining irradiation and
cetuximab also resulted in an increase of skin reactions
[18].
In conclusion, there are good reasons to expect improve-
ment of treatment results with respect to local tumour
control and acceptable toxicity on combining irradiation
and application of EGF-receptor antibodies.
The main purpose of the NEAR-trial (Non-small cell lung
cancer, Erbitux And Radiotherapy) is to evaluate the feasi-
bility and safety of a new treatment regimen in inoperable
NSCLC stage III by combining loco-regional irradiation
and weekly application of the monoclonal EGFR- receptor
antibody cetuximab (Erbitux®) in patients who are not eli-
gible for a radio-chemotherapy.
Methods/design
Trial organization
NEAR has been designed by the Trial Center of the Depart-
ment of Radiation Oncology, University of Heidelberg in
cooperation with the Thoraxklinik in Heidelberg. The trial
is carried out by the Department of Radiation Oncology
together with the German Cancer Research Center (DKFZ)
and Department of Medical Oncology of the Thoraxklinik
Heidelberg. The trial is an investigator initiated trial. Trial
medication (cetuximab) is supplied by Merck KGaA,
Darmstadt, Germany.
Coordination
The trial is co-ordinated by the Department of Radiation
Oncology of the University of Heidelberg in cooperation
with the DKFZ and the Department of Medical Oncology
at the Thoraxklinik Heidelberg. The Dept. of Radiation
Oncology is responsible for overall trial management,BMC Cancer 2006, 6:122 http://www.biomedcentral.com/1471-2407/6/122
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trial registration (ClinicalTrials.gov Identifier:
NCT00115518), database management, quality assurance
including monitoring, reporting and for the scientific pro-
gram of all trial related meetings.
Investigators
Patients will be recruited by the Department of Radiation
Oncology at the University of Heidelberg and by the
Department of Medical Oncology of the Thoraxklinik
Heidelberg. Due to the multi-modal nature of the trial, all
investigators are experienced oncologists from the fields
of radiation oncology and medical oncology.
Adverse events committee
This committee consists of 2 physicians (medical oncolo-
gist, radiation oncologist) and decides on the final diag-
nostic classification of critical clinical events. For all
serious adverse events the documentation and relevant
patient data are verified by the co-ordinating personnel
before submitting the data to the Adverse Events Commit-
tee for diagnostic classification.
Analysis of safety related data is performed with respect to
frequency of:
￿ Serious Adverse Events and Adverse Events stratified by
organ-system
￿ Adverse Events stratified by severity
￿ Adverse Events stratified by causality.
Patient toxicities will be assessed using the NCI Common
Toxicity Criteria (CTC). Toxicity will be evaluated prior to
treatment, weekly prior to each course of infusional
Cetuximab and at follow-up. Unacceptable toxicity is
defined as unpredictable, or irreversible Grade 4 toxicity.
Decisions regarding cetuximab dose-adjustment will be
made using the guidelines below and based on haemato-
logical parameters (ANC and platelets) monitored weekly
during radiation before each dose of cetuximab.
On-site monitoring
During recruitment of patients monitoring on site is per-
formed according to good clinical practice (GCP) guide-
lines. The data management will be performed by the Trial
Centre of the Department of Radiation Oncology, Univer-
sity of Heidelberg.
Ethics, informed consent and safety
The final protocol was approved by the ethics committee
of the University of Heidelberg, Medical School (L-284/
2004) and the Paul-Ehrlich-Institute ((PEI-registration
number 1209/01). This study complies with the Helsinki
Declaration in its recent German version, the Medical
Association's professional code of conduct, the principles
of Good Clinical Practice (GCP) guidelines and the Fed-
eral Data Protection Act. The trial will also be carried out
in keeping with local legal and regulatory requirements.
The medical secrecy and the Federal Data Protection Act
will be followed.
Written informed consent is obtained from each patient
in oral and written form before inclusion in the trial and
the nature, scope, and possible consequences of the trial
have been explained by a physician. The investigator will
not undertake any measures specifically required only for
the clinical trial until valid consent has been obtained.
Study design
The NEAR-study is a prospective phase II feasibility study
combining a monoclonal EGF-receptor antibody with
loco-regional irradiation in patients with stage III NSCLC.
This trial aims at testing the combination's safety and effi-
cacy and rate of development of distant metastases with
an accrual of 30 patients. These are treated by the Dept. of
Radiation Oncology and Radiation Therapy, University of
Heidelberg, in co-operation with the German Cancer
Research Centre (DKFZ), Heidelberg, the Dept. of Medical
Oncology, Thoraxklinik, Heidelberg, and the Dept. of
Nuclear Medicine, University of Heidelberg.
Primary endpoints are toxicities and feasibility of the
combined treatment.
Secondary endpoints are remission rates, 3-year-survival
and local/systemic progression-free survival.
Patient selection
In order to be included in the NEAR trial, patients were
required to have histologically confirmed NSCLC and
documented inoperable NSCLC stage III disease, where
combined chemo-radiotherapy is either deemed medi-
cally contra-indicated or refused by the patient. Each
patient is discussed by a commitee consisting of a thoracic
surgeon, a medical oncologist, a pulmonologist, a radiol-
ogist and a radiation oncologist. Evaluation of EGFR sta-
tus is recommended but not compulsory. Patients also
need to have sufficient remaining lung function (FeV1 ≥
1.5 l/s or at least 50% of the respective individual norm
value) as well as a Karnofsky Performance score of 70 %
or higher.
Patients should be ≥ 18 years and individual life expect-
ancy be estimated to ≥ 6 months. Accrued patients will be
expected to demonstrate sufficient compliance, they
should also live in relative proximity of the centre of care
to ensure adequate follow-up after treatment. In addition,
adequate haematological, hepatic, and renal function isBMC Cancer 2006, 6:122 http://www.biomedcentral.com/1471-2407/6/122
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essential for inclusion in the trial (wbc ≥ 3000 × 103 /ml,
thc ≥ 100 × 106 /ml, hb ≥ 10 g/dl).
Female patients are required to use adequate contracep-
tion during and at least up to 3 months after treatment.
Naturally, written informed consent is obtained prior to
commencement of treatment in this trial.
Patients are not eligible with active infections, inadequate
liver function (bilirubin ≥ 2 × above normal, GOT/GPT >
5 × above normal) or haemodynamically relevant haemo-
ptyses (hb-drop of 1 g/dl within 24 h), superior vena cava
syndrome, or malignant pleural effusions. Patients with
severe concurrent systemic disease or other malignant dis-
ease (apart from cervical carcinoma in-situ, basal cell car-
cinoma, or unless previously treated and in remission for
≥ 5 years without further treatment) can also not be
included in this trial. Furthermore, hypersensitivity to for-
eign proteins or x-ray contrast medium, or use of other
test substances within one month prior to commence-
ment of the NEAR trial and previous chemotherapy will
prohibit inclusion as will pregnancy or breast feeding.
Work-up
Patients with pathologically or cytologically documented
NSCLC stage III receive a complete work-up including
thoracic and cerebral CT scans, abdominal ultrasound,
bone scan (plus x-ray exams of suspect areas where appli-
cable). Patients with positive mediastinal lymph nodes,
(either pathologically documented or found suspect in
the CT-scan due to diameter >1.5 cm) will be sent for sur-
gical consultation and evaluation of operability. Should
operation be found impossible, in,-and exclusion criteria
are examined. In the event of patients meeting the
required inclusion criteria, information about participa-
tion in the study with possible risks and benefits is given
to the patients and written informed consent is obtained.
Patients can then be included in the study, documenta-
tion is provided by the study centre (Studienzentrale Kli-
nische Radiologie, Abt. Strahlentherapie und
Radioonkolgie, INF 400, 69120 Heidelberg).
After inclusion, patients are referred to FDG-PET scanning
in order to optimise target volume definition. Each
patient receives a radiation therapy planning CT-scan in
individually-adjusted precision immobilisation devices.
In the event of patients declining treatment within the
NEAR trial, irradiation alone is offered.
Safety and discontinuation of treatment
Toxicities are classified by grade, type, duration, onset,
and relationship to study treatment.
Treatment of cetuximab-induced adverse reactions is car-
ried according to recommendations by the provider.
For grade 1 or 2 allergic reactions, a decrease of infusion
rate for current and subsequent infusions is suggested. For
≥°3, persistent °1 or °2 allergic reactions despite reduc-
tion of infusion rate, it is recommended to discontinue
treatment with cetuximab. Skin reactions in terms of acne-
like rash after cetuximab are common. In patients with °3
acne-like rash cetuximab should be delayed for up to two
subsequent infusions. Treatment also includes concomi-
tant topical and/or oral antibiotics where necessary. Ther-
apy can be resumed on resolution of the rash to <°2.
Cetuximab needs to be delayed on a 2nd or 3rd occurrence
of a °3 skin reaction for up to two consecutive cycles with
dose reduction to 200 mg/m2 or 150 mg/m2 respectively.
Any further occurrence of grade °3 acne-like rash will lead
to discontinuation of cetuximab treatment.
Drug supply
The monoclonal antibody cetuximab (Erbitux®) is pro-
vided by Merck KGaA, Darmstadt, Germany, and stored
by the University Hospital Pharmacy, Heidelberg.
The respective cetuximab dose applied in this setting cor-
responds to the recommended and approved dosage
tested in combination with irinotecan in metastatic colo-
rectal carcinoma [19]. Cetuximab is given with a loading
dose of 400 mg/m2 as an intravenous infusion on day 1.
Subsequently, the regular weekly dose during radiother-
apy is 250 mg/m2 on days 8, 15, 22, 29, 36, 43, and 50.
After completion of irradiation, patients continue to
receive 250 mg/m2 weekly for another 13 weeks. Admin-
istration of cetuximab is discontinued if patients show
local or systemic progression.
Radiation therapy
Irradiation is applied as intensity-modulated radiation
therapy (IMRT). The primary tumour and mediastinal
lymph nodes receive a dose of 50 Gy in daily fractions of
2 Gy (Monday to Friday).
Primary tumour and involved lymph nodes are subse-
quently boosted to a total dose of 66 Gy in daily fractions
of 2 Gy. Tolerances of thoracic organs at risk should not
be exceeded.
The schedule of the treatment is shown in Figure 1:
Supportive therapy
Whenever necessary, metoclopramide or 5-HT3-antago-
nists are used for antiemesis.
Antihistamines such as clemastine or dimetinden and
steroids are administered prior to cetuximab-application.BMC Cancer 2006, 6:122 http://www.biomedcentral.com/1471-2407/6/122
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Skin reactions, especially acne-like rashes can be treated
by topic or systemic antibiotics (i.e. tetracyclines or met-
ronidazole) if necessary. Radiation induced skin reactions
are treated according to in-house protocols with mild
moisturizing lotion (i.e. Bepanthen®-lotio) or local appli-
cation of steroids.
Trial duration
Individual participation is completed either three years
after enrolment or death of the patient.
Individual exclusion criteria are serious adverse reactions
or the patient's voluntary withdrawal from the trial.
Assessment of therapeutic efficacy
Methods/Investigations
￿ Chest x-ray on completion of irradiation to exclude dis-
ease progression under current treatment
￿ CT-thorax q3 months until completion of study
￿ Abdominal ultrasound q6 months until completion of
study
￿ Bone scan q12 months until completion of study
￿ FDG-PET scan prior and after completion of the treat-
ment (last cetuximab infusion)
Evaluation
Local response is evaluated in accordance with the RECIST
Criteria (Response Evaluation Criteria in Solid Tumours)
[21].
1. complete remission (CR): is defined as complete regres-
sion of the treated tumour mass (confirmation after at
least 4 weeks of treatment or later)
2. partial remission (PR) is defined as reduction of sum of
largest tumour diameters by at least 30% (confirmation
after at least 4 weeks of treatment or later)
3. stable disease (NC := no change): neither PR nor PD
4. progressive disease (PD): increase of sum of largest
tumour diameters by 20%
Discussion
Definitive radiation therapy as a single modality approach
leads to a permanent cure only in a minority of patients
with inoperable NSCLC stage III. Outcome in this group
of patients was improved by administering concurrent
radio-chemotherapy and combining local irradiation
with various systemic platinum-based chemotherapy reg-
imens. However, toxicities also increase in the combined
modality approach so a major part of the respective
patients are unfit to receive this combined treatment. One
possible alternative could be the combination of irradia-
Chart of the treatment schedule of the NEAR trial Figure 1
Chart of the treatment schedule of the NEAR trial.
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tion with an EGF-receptor antibody like cetuximab. A
phase III trial in head and neck tumours was already able
to demonstrate significantly improved tumour response
and overall survival on combining local irradiation with
cetuximab vs. irradiation alone. These results were even
comparable to standard radio-chemotherapy regimen in
this setting.
Considering previous results with cetuximab by other
investigators, there is a legitimate hope that side-effects
can be minimised by a combined treatment of irradiation
and cetuximab and will be mild in comparison to the
standard radio-chemotherapy regimen. Also, by IMRT-
treatment planning, normal tissue will be more ade-
quately spared while allowing dose escalation to the gross
tumour volume. Thus, this treatment might become an
option even for patients otherwise unfit to receive the
standard combined radio-chemotherapy regimen.
The NEAR trial was designed to evaluate the feasibility
and toxicity of a combined treatment with irradiation and
a standardised dosage of the monoclonal EGFR antibody
cetuximab (Erbitux®) in inoperable NSCLC stage III.
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